BRCA2 and ductal breast carcinoma in situ: When BRCA1 and BRCA2 mutation-related cases were examined together, HIF-1α expression in DCIS matched the expression in the accompanying invasive cancers in 68% (31/45) of cases, as compared to in 68% (34/50) of the non-BRCA mutation carrier cases.